News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Alfonso Duenas Gonzalez: Quite odd, do not you believe?
Alfonso Duenas Gonzalez/cyd.conacyt.gob.mx
May 11, 2025, 13:56

Alfonso Duenas Gonzalez: Quite odd, do not you believe?

Alfonso Duenas Gonzalez, Medical Oncologist and Senior Researcher at National Cancer Institute of Mexico, shared a post on X:

“Dear All, For your knowledge. Quite odd, do not you believe?”

Alfonso Duenas Gonzalez: Quite odd, do not you believe?

More posts featuring NCI on OncoDaily.

Alfonso Duenas Gonzalez cancer fight against cancer Global fight against cancer MedOnc National Cancer Institute NCI OncoDaily Oncology
Special Coverage
Blog
Jun 1, 2025, 06:58
Noha Soror Thanks ASCO 2025 Attendees for Poster Session Engagement
Blog
Jun 1, 2025, 06:42
Charu Aggarwal: Fantastic Representation of Thoracic Oncology ASCO25 Posters
Blog
Jun 1, 2025, 06:36
Sid Sadler: New Era for Renal Cell Carcinoma Patients
Blog
Jun 1, 2025, 06:27
Alfonso Gómez de Liaño Highlights CREST Trial Insights in BCG-Unexposed Bladder Cancer at ASCO 2025
Blog
Jun 1, 2025, 06:15
Gaia Griguolo: PROs from EMBER3 Trial Presented at ASCO25
Blog
Jun 1, 2025, 06:13
An Outstanding Mentor: Kelly Meza Reflects on the Impact of Naveen Pemmaraju’s Mentorship in Oncology
Blog
Jun 1, 2025, 06:11
Aakash Desai: It’s Only Saturday of ASCO25 and My Heart is Full
Career
Jun 1, 2025, 06:06
Maite Bourlon: Very Proud of Fernanda Rivera for Receiving the 2025 Conquer Cancer, the ASCO Foundation IDEA Award
Blog
Jun 1, 2025, 06:05
Heidi Ko: What ASCO25 Means to Me as an Oncologist
Blog
Jun 1, 2025, 06:00
Margherita Ambrosini Highlights ARMANI Trial Findings in HER2-Negative Gastric Cancer at ASCO 2025
Opinion
Jun 1, 2025, 05:59
Shabnam Gujadhur: Day 1 at ASCO 2025 Was All About the Human Side of Oncology
Opinion
Jun 1, 2025, 05:57
EMBER-3 trial Results: Patient-Reported Outcomes with Imlunestrant ± Abemaciclib vs Standard Endocrine Therapy in ER+/HER2− Advanced Breast Cancer